Princeton Alpha Management’s Ligand Pharmaceuticals LGND Stock Holding History

Princeton Alpha Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-4,870	Closed	-$310K	–	790
2016 Q3	$310K	Buy	+4,870	New	+$358K	0.06%	486
2015 Q3	–	Sell	-3,350	Closed	-$211K	–	825
2015 Q2	$211K	Buy	+3,350	New	+$183K	0.04%	581
2014 Q4	–	Sell	-8,530	Closed	-$250K	–	766
2014 Q3	$250K	Buy	8,530 +1,892	+29%	+$62.8K	0.06%	493
2014 Q2	$258K	Buy	+6,638	New	+$269K	0.05%	495

Other funds holding LGND

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Princeton Alpha Management's LGND Position: Q4 2016 in Review

Princeton Alpha Management sold out of Ligand Pharmaceuticals (LGND) in Q4 2016, closing a stake of 4,870 shares — an estimated $310K sold.

Princeton Alpha Management first reported a position in LGND in Q2 2014 and held it in 4 quarters. The position peaked at $310K in Q3 2016. 269 funds tracked by Wall St. Rank hold LGND as of Q4 2016.

Princeton Alpha Management reported no remaining Ligand Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Princeton Alpha Management sold 4,870 Ligand Pharmaceuticals shares in Q4 2016, an estimated $310K.
Princeton Alpha Management first reported a position in Ligand Pharmaceuticals in Q2 2014 and held it in 4 quarters.
Princeton Alpha Management's Ligand Pharmaceuticals position peaked at $310K in Q3 2016.
269 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2016.

Based on Princeton Alpha Management's 13F filing for Q4 2016, filed 10 Feb 2017.